Diabetes is a condition that has many variables. Researchers are finding more and more about how genetics and patient behavior play a role; however, it turns out that socioeconomic status, education, and ethnic background all play a role as well.
On Monday afternoon, Jessica Robbins, PhD, member of the Philadelphia Department of Public Health and Adjunct Professor at Drexel, presented on the role of socioeconomic status in diabetes risk and outcomes. The overarching framework used for this discussion was the social ecological framework. Dr. Robbins presented alarming data regarding the disparity of diabetes prevalence both in terms of racial background and socioeconomic status. Here are some of the general observations that Dr. Robbins presented along with references to both local and national studies:
- The African American population continues to show more susceptibility to diabetes than non-Hispanic whites, and this pattern is consistent across many studies
- Household income is an excellent predictor of diabetes prevalence; households with $50,000/year in income had half as much a rate of incidence (5%) as those which have $35,000/year (10%)
- Exploring Health Disparities in Integrated Communities (EHDIC) Study found that whites and African Americans in integrated communities had similar odds of having diabetes, despite substantial racial/ethnic disparities at the population level
- Diabetes disparities are greater in women than men, both in terms of racial background and socioeconomic status
- Disparities decline by age, especially among the very old, although this may reflect measuring issues
- Some studies have found that those who go to college have the lowest risk of contracting diabetes, both in racial and gender groups
- The DISTANCE cohort study (Kaiser Permanente Southern California) found disparities in glycemic control and other intermediate clinical outcomes were associated with the socioeconomic status of patients’ area of residence
Although there have been numerous studies conducted to analyze the various factors that are associated with diabetes, there still remains widespread debate as to which factors are more revealing than others, especially when considering that many of these factors are interrelated. However, Dr. Robbins concluded by saying that the effects of socioeconomic status on diabetes outcomes are without question “big, not inevitable, and unacceptable.”
For more information on this session, please visit the American Diabetes Association’s website.
Social Epidemiology of Diabetes
Diabetes is a condition that has many variables. Researchers are finding more and more about how genetics and patient behavior play a role; however, it turns out that socioeconomic status, education, and ethnic background all play a role as well.
Diabetes is a condition that has many variables. Researchers are finding more and more about how genetics and patient behavior play a role; however, it turns out that socioeconomic status, education, and ethnic background all play a role as well.
On Monday afternoon, Jessica Robbins, PhD, member of the Philadelphia Department of Public Health and Adjunct Professor at Drexel, presented on the role of socioeconomic status in diabetes risk and outcomes. The overarching framework used for this discussion was the social ecological framework. Dr. Robbins presented alarming data regarding the disparity of diabetes prevalence both in terms of racial background and socioeconomic status. Here are some of the general observations that Dr. Robbins presented along with references to both local and national studies:
Although there have been numerous studies conducted to analyze the various factors that are associated with diabetes, there still remains widespread debate as to which factors are more revealing than others, especially when considering that many of these factors are interrelated. However, Dr. Robbins concluded by saying that the effects of socioeconomic status on diabetes outcomes are without question “big, not inevitable, and unacceptable.”
For more information on this session, please visit the American Diabetes Association’s website.
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
December 5th 2025Read More
Challenges, Opportunities in Implementing the MDPP: Melanie T. Turk, PhD, RN
October 21st 2025Melanie T. Turk, PhD, RN, discusses her study on nationwide challenges program suppliers face in implementing the Medicare Diabetes Prevention Program (MDPP).
Listen
Tech Offers Empathy but Digital Divide Looms in Respiratory Health Care
November 25th 2025While artificial intelligence showed empathy and precision in respiratory health care, its equitable adoption is paramount to prevent the widening digital divide, as highlighted at the European Respiratory Society Congress 2025.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
CAVIAR: Alirocumab Safely Lowers Cholesterol After Heart Transplant
November 10th 2025The trial did not meet its primary end point for reducing plaque progression.
Read More
POLY-HF: Polypill Boosts Heart Function, Adherence in Heart Failure
November 10th 2025Combining 3 standard therapies into a single pill improved outcomes for adults with heart failure with reduced ejection fraction.
Read More
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
December 5th 2025Read More
Challenges, Opportunities in Implementing the MDPP: Melanie T. Turk, PhD, RN
October 21st 2025Melanie T. Turk, PhD, RN, discusses her study on nationwide challenges program suppliers face in implementing the Medicare Diabetes Prevention Program (MDPP).
Listen
Tech Offers Empathy but Digital Divide Looms in Respiratory Health Care
November 25th 2025While artificial intelligence showed empathy and precision in respiratory health care, its equitable adoption is paramount to prevent the widening digital divide, as highlighted at the European Respiratory Society Congress 2025.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
CAVIAR: Alirocumab Safely Lowers Cholesterol After Heart Transplant
November 10th 2025The trial did not meet its primary end point for reducing plaque progression.
Read More
POLY-HF: Polypill Boosts Heart Function, Adherence in Heart Failure
November 10th 2025Combining 3 standard therapies into a single pill improved outcomes for adults with heart failure with reduced ejection fraction.
Read More